Market Watch: Mesoblast shares down 14%
Monday, 31 October, 2011
The share price of stem cell specialists Mesoblast (ASX:MSB) shed 14% of its value in trading on Friday and today, down from $9.39 at Thursday’s close of trading to $8.25 as of midday today.
The drop was precipitated by Macquarie Research updating its rating for the biotech to “underperform”.
Other analysts have recently rated Mesoblast as “buy”, with Nomura setting a target price of $10.15 and Bell Potter $16.00 both only one month ago.
Late last year Mesoblast wowed the industry with its monumental deal with Cephalon, and recently announced it was partnering with Lonza to manufacture it’s off-the-shelf mesenchymal precursor stem cells.
Follow this link for a detailed profile of Mesoblast and its technology, and an interview with its CEO, Professor Silviu Itescu.
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
